nach oben

Erschienen in:

01.11.2011 | News item

Linezolid, methylene blue: serotonin syndrome update

Erschienen in: Reactions Weekly | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Excerpt

In July 2011, the US FDA issued drug safety communications for linezolid [Zyvox] and methylene blue [metylthioninium chloride], regarding the associated risks of serotonin syndrome in patients taking concomitant serotonergic psychiatric medications.* The Agency is now updating the public with further details regarding these warnings.1 ^, 2 …

FDA.FDA Drug Safety Communication: Updated information about the drug interaction between methylene blue (methylthioninium chloride) and serotonergic psychiatric medications. Internet Document: 20 Oct 2011. Available from: URL: http://www.fda.gov

FDA.FDA Drug Safety Communication: Updated information about the drug interaction between linezolid (Zyvox) and serotonergic psychiatric medications. Internet Document: 20 Oct 2011. Available from: URL: http://www.fda.gov

Titel: Linezolid, methylene blue: serotonin syndrome update
Publikationsdatum: 01.11.2011
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2011
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.2165/00128415-201113760-00005

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Linezolid, methylene blue: serotonin syndrome update

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Ritodrine

S-1

RASI use risk factor for IVIG-induced renal failure

Cotrimoxazole/sulfasalazine/zonisamide

Etidronic acid

Progression-free survival more important than ADRs in RCC